Top 10 Best-selling Cancer Drugs

Fierce Pharma | Tracy Stanton

Oncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development, as the upcoming American Society of Clinical Oncology meeting will attest. The usual reasons for growing drug demand apply: Rising healthcare spending in countries such as China; an expanding middle class better able to access healthcare in India and other emerging markets; and aging populations in big drug markets like the U.S. and Japan.

Inside The Secret World Of Drug Company Rebates

Forbes | Matthew Herper

The free market is alive and well when it comes to drug prices – if you’re an insurance company or a government program. But not if you’re a consumer.

Top-selling pharmaceuticals, protected by patents, often seem priced in a manner that has little to do with the laws of supply and demand. Want that new cholesterol medicine ($2,000 per year), that cancer treatment ($60,000 per year) , or the medicine for your child’s rare disease ($300,000 per year)? No negotiation. It’s your money or your life.

But in fact drug companies are constantly negotiating, not with individuals but with payers – Medicare, Medicaid, insurers such as United Health Care and Aetna and pharmacy benefit plans such as Express Scripts. They don’t reduce the price of their medicines. Instead, the drug firms pay rebates after the fact. For Medicaid, the price decreases are mandated by law, but everywhere else, free market forces are very much in effect. Me too drugs and those facing patent expiration have to deal with bigger rebates. Drug firms annual price increases are partly a way to deal with all this rebating. Of course, if you’re a person without health insurance buying medicines at the counter of Walgreen‘s, you’re stuck with the list price.

Medical device market will reach $415B in 2016

Despite austerity movements around the globe and the impending U.S. device tax, the global market for medical devices will grow to $415 billion in 2016, according to analysis from Kalorama Information.

Despite the threats of unfavorable policies for devicemakers, Kalorama predicts growth on the strength of emerging market sales and aging populations in need of devices. All of that will bring the market to $415 billion from 2011's $322 billion.

Φαρμακευτικο Μαρκετινγκ: Θεωρια, Πρακτικη, Δεοντολογια

The ultimate guide for Pharma Marketing Champions

Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…

http://www.stamoulis.gr/ViewShopProduct.aspx?ProductId=402023

Κατεβάζουν τα ρολά οι φαρμακοποιοί από την Τετάρτη 23 Μαΐου.

Κατά τη χθεσινή έκτακτη σύσκεψή τους, οι φαρμακοποιοί όλης της χώρας αποφάσισαν ομόφωνα να προχωρήσουν σε κινητοποιήσεις την ερχόμενη εβδομάδα εξαιτίας των οφειλών του Ενιαίου Οργανισμού Παροχής Υπηρεσιών Υγείας (ΕΟΠΥΥ).

Συγκεκριμένα, στις 23 Μαΐου τα φαρμακεία θα παραμείνουν κλειστά. Από την ίδια μέρα δεν θα χορηγούνται φάρμακα με πίστωση στους ασφαλισμένους του ΕΟΠΥΥ. Οι ασθενείς – ασφαλισμένοι του εν λόγω Ταμείου θα αγοράζουν οι ίδιοι τα φάρμακά τους και στη συνέχεια θα διεκδικούν τα χρήματά τους από τον Οργανισμό.

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe

Abbott yesterday announced that the XIENCE PRIME™ and the XIENCE V® Everolimus Eluting Coronary Stent Systems have received CE Mark in Europe for the use of dual anti-platelet therapy (DAPT) for at least three months after stent implantation in patients with coronary artery disease. This is the shortest duration of DAPT for any major drug eluting stent (DES) in Europe.

Sales forces shrank in 2011, but not everywhere

Medical marketing & Media | Matthew Arnold    

Pharmas shrank their US sales forces by 7% between 2010 and 2011, but the pain wasn't shared evenly between the biggest of pharmas, as a number of players scaled up.

Roche cut deepest among big pharmas, lopping off a third of its Full-Time Rep Equivalents, while Abbott and Sanofi were close behind, downsizing 23% of their FTEs, according to an analysis by Cegedim Strategic Data. GSK cut its FTE force by 22% and Bayer by 19%.

GlaxoSmithKline announces acquisition of Cellzome

GlaxoSmithKline has announced plans to fully acquire Cellzome, a leading provider of technology for the development and advancement of proteomics.

The pharmaceutical company will pay 61 million pounds to purchase all remaining shares in Cellzome, a UK and Germany-based organisation in which GlaxoSmithKline already owns a 19.98 percent equity stake.

Pharma funds drug discovery partnership

Half a dozen pharma firms are contributing £14.4 million to work by Dundee University and the Medical Research Council (MRC) on speeding up drug discovery. 

AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Merck-Serono and Pfizer are involved in a consortium called the Division of Signal Transduction Therapy (DSTT), and will put in the money over four years from July.

International Clinical Trials Day: 20 May 2012

The European Medicines Agency supports International Clinical Trials Day, which is taking place on Sunday 20 May 2012.

International Clinical Trials Day aims to enhance communication and coordination of clinical trials between countries, resulting in better clinical research that is relevant to the needs of patients everywhere. It is celebrated every year on or around 20 May, commemorating the day that James Lind started his famous trial comparing treatments for scurvy on 20 May 1747.